# Invivyd Chairman Marc Elia Appointed CEO Ahead of COVID-19 Data Readout

Infectious-disease biotech Invivyd has named its current chairman, Marc Elia, as the company’s new chief executive officer. The appointment comes as the company prepares to release clinical data for its COVID-19 antibody candidate.

Elia had been serving as chairman of Invivyd’s board of directors. He now assumes the CEO role in addition to his chairmanship. The timing of the leadership change coincides with an upcoming readout from Invivyd’s ongoing clinical program.

Invivyd focuses on developing monoclonal antibody therapies for viral infectious diseases, with its lead program targeting SARS-CoV-2. The company’s pipeline includes candidates designed to provide protection against emerging variants of the virus.

**Why it matters**

Leadership transitions at clinical-stage biotechs often signal a shift in strategic direction or an effort to align management with near-term milestones. In Invivyd’s case, placing the chairman in the CEO role ahead of a pivotal data readout may indicate a push to streamline decision-making as the company seeks regulatory and commercial progress. For the broader life-sciences sector, the outcome of Invivyd’s COVID-19 antibody program could affect the competitive landscape for next-generation treatments, particularly as the virus continues to evolve and new variants emerge.

Source: [original report](https://www.fiercebiotech.com/biotech/chutes-ladders-invivyd-boosts-chairman-ceo-ahead-covid-readout)